POPULARITY
Categories
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels. Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said. “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.” Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas. The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/ XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition. G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment. The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes. "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes. The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November. https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/ XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. , The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say. In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries." The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours. Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy. At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy. Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells. Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially. Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells. “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release. “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification
人工智慧(AI)如何改變藥物開發?藥物開發從臨床前研究到臨床試驗,通常需要超過十年時間和數十億美元的投資,卻仍有高達九成的藥物在臨床試驗中失敗。這些挑戰,現在 AI 正在各種方面掀起革命。在這系列節目中,我們將探討 AI 在藥物開發領域中的應用,並介紹在這個快速發展的領域中工作的專家。 本集為《AI 藥物開發系列》的第三集。我們邀請到加州大學聖塔克魯茲分校的葉先偉教授。他曾在諾貝爾獎得主 David Baker 的實驗室進行博士後研究。本集主題將探討 AI 蛋白質設計,介紹他如何設計新型 luciferase 與生物感測器 biosensor,並講解 2024 年諾貝爾獎的研究,以及他對於 AI 蛋白質設計未來發展的看法。
Faça sua assinatura! www.resumido.cc/assinatura--China ultrapassa o mundo em número de robôs, carpinteiros são contratados para serem filmados para treinamento de IA e pessoas vendem as próprias ligações também para isso. O ChatGPT quer tomar conta do seu dia, startups criam cópias de arte tão perfeitas que abrem um novo mercado. Pelo menos o Instagram promete nos dar algum controle do algoritmo.Qual o preço das nossas experiências?No RESUMIDO #332: China lidera corrida global dos robôs, carpinteiros viram espetáculo ao vivo, plataforma paga por ligações telefônicas para treinar IA, Geração Z tenta blindar carreira contra substituição tecnológica, Instagram atinge três bilhões de usuários promete controle sobre algoritmo e muito mais!--Ouça e confira todos os links comentados no episódio: https://resumido.cc/podcasts/robos-chegaram-falsas-promessas-da-ia-controle-seu-feed
Anna Wood, Editor at Startups Magazine, speaks to Mark Sweeny, Founder and Group Chief Executive de Novo Solutions, all about always focusing on the fundamentals, championing the Welsh ecosystem and winning the Most Successful Scaleup Award at the Hustle Awards 2025.
Anna Wood, Editor at Startups Magazine, speaks to Mark Sweeny, Founder and Group Chief Executive de Novo Solutions, all about always focusing on the fundamentals, championing the Welsh ecosystem and winning the Most Successful Scaleup Award at the Hustle Awards 2025.
O TCU (Tribunal de Contas da União) avisou ao governo que é preciso buscar o centro da banda prevista no arcabouço fiscal, e não o limite inferior. A mudança ameaça o planejamento do Executivo para o ano que vem, quando o presidente Lula (PT) pretende disputar a reeleição. A analista de Economia da CNN Thais Herédia, o analista de Política da CNN Caio Junqueira e Jeferson Bittencourt, economista do ASA e ex-secretário do Tesouro, debatem o assunto.
Acredite se quiser mas o Xbox vai aumentar de preço DE NOVO. O Series S agora vai partir de 400 dólares e o Series X pode chegar a 800 dólares, o que daria facilmente 8 mil reais por aqui! O que está acontecendo? A Microsoft enlouqueceu? Entenda tudo sobre o assunto na nossa Treta da Semana.
Futebol, informação, humor, opinião e corneta! Um programa de debate sobre tudo que envolve futebol de um jeito descontraído e animado. Veja muito mais no YouTube
Muita especulação e rumores sobre Resident Evil: Village. O nono capítulo da saga vai trazer uma nova protagonista, Grace, mas o queridinho dos fãs Leon S. Kennedy também deve dar as caras, se os vazamentos forem reais. Mas o galã de Resident Evil 2 está com um novo visual e cara de pouquíssimos amigos. Correndo por fora, a Microsoft aumentou os preços de seu Xbox Series mais uma vez, com edições que pode chegar a salgados 800 dólares. O Flow Games News de hoje tá
O PodRei, um podcast da TV Unifor, é produzido pelo Núcleo de Produção de Podcasts nos estúdios da Unifor. Apresentado por quatro estudantes de Jornalismo apaixonados pelo futebol cearense, o programa se dedica à cobertura semanal de tudo o que acontece com os times do Fortaleza e do Ceará. ⚽Ficha técnicaApresentadores: Eduarda Sena, Matheus Pinheiro, João Pedro Moreira, Felipe Assis e João Bosco Neto.Produção: Eduarda Sena, Matheus Pinheiro, João Pedro Moreira, Felipe Assis e João Bosco Neto, Beatriz Barros, Clara Cezarino e Samuel Pordeus.Orientação: Ana Paula Farias e Max EluardDireção: Max Eluard
Summary del Show: • Wall Street sube tras el primer recorte de tasas de 2025 por parte de la Fed, aunque persiste incertidumbre sobre el ciclo de flexibilización. • Nvidia $NVDA e Intel $INTC anuncian un acuerdo histórico para codesarrollar chips y $NVDA invierte $5B en acciones de Intel. • Palantir $PLTR cierra un contrato por £1.5B con el Reino Unido, convirtiendo a Londres en su hub europeo de defensa. • Novo Nordisk $NVO gana impulso tras datos clínicos que muestran ventaja cardiovascular de Ozempic frente a Trulicity de Eli Lilly $LLY.
Tema – A evidência de um coração nascido de novo. Quarta – Feira 17/09/2025 Pregador : Ap. Miguel Ângelo Neste sermão impactante, o Apóstolo Miguel Ângelo revela o coração do evangelho: o novo nascimento. Com base na conversa entre Jesus e Nicodemos, aprendemos que não são os rituais, nem as tradições, que salvam — mas sim uma obra profunda do Espírito Santo no interior do ser humano. A verdadeira evidência de um coração nascido de Deus é a regeneração, que transforma desejos, valores, afetos e dá uma nova identidade espiritual. Quem nasce de Deus não vive mais na prática do pecado, mas em comunhão com Cristo e com a igreja. Esta mensagem é um convite à reflexão, ao arrependimento genuíno e à certeza da salvação. Prepare-se para ser confrontado e edificado com a verdade que liberta e transforma. Assista até o fim e experimente o poder de uma vida verdadeiramente renovada por Deus. Aula 22 Módulo – 66 Seminário: Construindo uma casa sobre a Rocha
SEMANA 2 DA TEMPORADA 2025 DA NFL!
Edgard Maciel de Sá, Cauê Rademaker, Phill e Marcello Neves analisam a derrota para o Lanús, os erros de Renato, o planejamento dos últimos jogos e a necessidade de vencer o Vitória pelo Brasileirão. DÁ O PLAY!
nem tudo é sua culpa, mas algumas coisas são sua responsabilidade.
O candidato à presidência do Benfica, João D. Manteigas, considera que face aos resultados, Rui Costa, "devia desistir da recandidatura". Considera que contratar um novo treinador compromete o futuro.See omnystudio.com/listener for privacy information.
O cérebro e o pensamento ideológico; o Relatório Global sobre o Estado da Democracia; reportagem no Centro Unbroken de Lviv; Gaza e França. Visão Global, edição de José Guerreiro.
O PodRei, um podcast da TV Unifor, é produzido pelo Núcleo de Produção de Podcasts nos estúdios da Unifor. Apresentado por quatro estudantes de Jornalismo apaixonados pelo futebol cearense, o programa se dedica à cobertura semanal de tudo o que acontece com os times do Fortaleza e do Ceará. ⚽Ficha técnicaApresentadores: Eduarda Sena, Matheus Pinheiro, João Pedro Moreira, Felipe Assis e João Bosco Neto.Produção: Eduarda Sena, Matheus Pinheiro, João Pedro Moreira, Felipe Assis e João Bosco Neto, Beatriz Barros, Clara Cezarino e Samuel Pordeus.Orientação: Ana Paula Farias e Max EluardDireção: Max Eluard
Olá amigos! Mais um episódio extra garantido pela meta coletiva dos nossos amigos assinantes, mais uma vez muito obrigado!! E olha aí, se estamos fazendo mais um pré-relato de vagem, quer dizer que estamos prestes a viajar novamente aeeeeee….. E olha só, estamos mais uma vez voltando pra Flórida, pra Orlando e para mais um […]
Mais uma Queniana pega no anti doping mas agora nas montanhas, abrem hoje as inscrições para a Maratona de Floripa 2026, prefeitura de Fortaleza mexe nas regras de corrida na Beira-Mar e uma entrevista com a brasileira que trabalha na World Athletics.#corrida #corridaderua #corridaderuabrasil #criadorporesporte #worldathletics #cnanews
In this episode, I sit down with Dr. Ben Fishbein — founder of Fishbein Orthodontics, multiple-time DeNovo opener, bagel store entrepreneur, and Smile Doctors partner — to break down one of the most misunderstood topics in orthodontics today: DSOs, OSOs, and what it really means to join one.If you've ever said, “I'm not ready,” “I could never give up control,” or “I don't need help,” this episode is for you. Ben was once a staunch no—until he actually had the conversation. Now, with multiple thriving practices, ownership in a national DSO, and an expanding local business portfolio, he shares what changed his mind—and why most orthodontists are asking the wrong questions entirely.Whether you're exploring a potential sale, considering DeNovos, or just want to sharpen your vision, this episode will reframe how you think about your career path—and the opportunities right in front of you.QUOTES"The most frustrating thing to me is when someone says, ‘I'm not ready to talk yet.' Why are you not ready to learn something that might be so good it changes your life?"— Dr. Glenn Krieger"I was a naysayer too. I told the Smile Doctors team, ‘There's less than a 2% chance I do this.' Then I listened—and it all started making sense."— Dr. Ben FishbeinKey Takeaways04:50 – Why so many orthodontists dismiss DSOs without ever really hearing the facts06:50 – “30 years in 7” — how Ben's early hustle shaped his future faster08:36 – Why listening to opportunities is part of your duty to your team10:15 – Why selling a practice isn't selling out—and how orthodontists misjudge entrepreneurship15:12 – How partnering opened Ben's eyes to investments he never considered before16:48 – The surprisingly valuable business lessons from running a bagel shop20:19 – Why Smile Doctors' DeNovo model works—and how it's redefining growth24:18 – “Get the information. Don't say no to something you don't understand.”25:37 – Ben's biggest advice to younger orthodontists: “Just go for it.”Additional Resources I've seen firsthand how running the numbers—really running them—has changed the trajectory of practices and lives.Want to get in contact with Ben? https://amandafloydconsulting.com/fishbein-fundamentals This isn't about selling out or giving up control. It's about knowing your options, making smart financial moves, and understanding when an opportunity might never come back. If you've received an offer and aren't sure whether to take it, DM me. I don't get paid either way—but I've had this conversation hundreds of times and I'll help you think it through.
O Bate-Pronto de hoje atualizará e debaterá as principais informações do futebol mundial. O destaque ficará por conta da Seleção Brasileira, que terá mudanças na escalação para enfrentar a Bolívia, amanhã, na altitude. O programa também repercutirá mais um título de Rogério Ceni como treinador e muito mais!
Neste domingo, GP da Itália, 16ª de 24 etapas da F1 2025. Por isso, o Podcast Motorsport.com chega com o PÓDIO, no qual o comentarista convidado Felipe Motta, apresentador da ESPN e ex-repórter de F1 in loco, debate o GP com Carlos Costa (@ocarlos_costa) e Isa Fernandes (@isamfer_).Bitcoin e criptomoedas? Invista na Mynt, plataforma cripto do BTG Pactual - https://bit.ly/425ErVa NASCAR XFINITY E CUP SERIES: Assista com o Motorsport! - https://tinyurl.com/4f3hbjnm MITSUBISHI CUP EM MOGI - https://www.youtube.com/live/mRibAdnC_cQ?si=fKFwSpVzXcC-oWGl
Ecoutez Laissez-vous tenter - Première avec Isabelle Morini-Bosc du 01 septembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.
Neste sábado, classificação para o GP da Holanda, 15ª de 24 etapas da F1 2025, o grande retorno das férias da categoria. Por isso, o Podcast Motorsport.com chega com o Q4, em que Erick Gabriel (@erickjornalista) e Isa Fernandes (@isamfer_) recebem Fabio Tarnapolsky (@fabiotarna), ex-Motorsport, ESPN e Estadão para o debate.Bitcoin e criptomoedas? Invista na MYNT, a plataforma cripto do BTG Pactual - https://bit.ly/425ErVa NASCAR XFINITY, TRUCK E CUP SERIES: Assista com o Motorsport! - https://tinyurl.com/4f3hbjnm
In this episode of the Group Practice Accelerator podcast, Jamie sits down with Polaris in-house strategist, Founder & CEO, Diwakar Sinha to explore the growing appeal of the de novo strategy in dentistry. Instead of, or in addition to, acquiring existing practices, more dentists and DSOs are choosing to build from the ground up—and for good reason. Diwakar shares his insights into what de novos can offer within your growth strategy, and hints at an opportunity to learn firsthand what it takes to launch one successfully.
Neste episódio, falamos sobre a zebra histórica da eliminação do Manchester United na Copa da Liga Inglesa para um time de quarta divisão. Além disso, o podcast aborda a vitória sofrida do Bayern na Copa da Alemanha contra o Wiesbaden e a vitória dramática do Liverpool contra o Newcastle na Premier League. A impressionante estreia da Inter de Milão na Serie A também a pauta! E tem entrevista especial e muito mais! Vem com a gente! Learn more about your ad choices. Visit podcastchoices.com/adchoices
Crônicas da Cidade - 28/08
In this episode, we review the high-yield topic of De Novo Nucleotide Synthesis from the Biochemistry section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Quer saber tudo que aconteceu no mercado financeiro, nacional e internacional? Acompanhe o nosso Fechamento de Mercado e confira com quais as ações que mais mexeram com a B3, movimentação do câmbio e dos juros e muito mais! O Fechamento de Mercado da Genial é transmitido de segunda a sexta, às 17h30. Ative as notificações do programa e acompanhe ao vivo!
DSD 6.8 | That is where you should put your money For years researchers have sought out to better understand control mechanisms for a successful transition into lactation from the dry period. We've learned changing body condition score during the dry period is not acceptable, but what if it changes during late lactation? How does this impact energy partitioning for the next lactation? Well managed high producing cows with high fertility might find themselves bred back in less than the “textbook ideal” condition score heading into the dry period. Can we alter the late lactation ration to successfully increase condition with little impact? Dr. Laura Hernandez from the University of Wisconsin worked with a team of researchers at the Forage Center to better understand what is happening if high energy is fed late in lactation through extensive data collection to determine the possible potential carry over effects for subsequent lactations. Listen into this compelling discussion as we learn more about the “black box” we know as the transition dairy cow and what phase to invest in to maximize your return. Topics of discussion 1:01 Goal of this month's research 1:40 Introduction of Dr. Laura Hernandez 2:52 Why is this topic important 5:09 Test ration design for increasing BCS in late lactation 3.25 vs 3.75 8:45 Cow responses to the ration 11:05 Figure 1a: BCS change over 12 weeks 11:45 Dry matter intake 10:27 Possible hormonal responses causing the 13:49 Energy partitioning 16:12 Genetic analysis for response and non-response 18:40 Dry cow and early ration following treatment 19:19 High energy effect on dystocia 20:50 Early lactation energy measurements 22:45 Close up - Intake differences of high and low energy 23:23 Fig 3d: Early lactation intake difference 24:44 Visceral fat changes 26:54 Denovo fatty acids in milk, 70 days post treatment 30:54 Concentration of Megalac in treatment ration 31:57 Description of animals on treatment 32:47 What do you want “boots on the ground” dairymen to learn from this project? Featured Article: Effects of high-energy and low-energy diets during late lactation on the subsequent dry period and lactation of Holstein dairy cows #2xAg2030; #journalofdairyscience; #openaccess; #MODAIRY; #transition; #latelactation; #earlylactation; #dmi; #NEFA; #BHB; #drycow; #dairysciencedigest; #ReaganBluel
Seja apoiador do X do ControleCompre seus jogos na Nuuvem! MARCAÇÕES DE TEMPO0:00:00) - Abertura(0:05:56) - Publicidade (0:06:44) - Steam perde mais um meio de pagamento por ação de ONG conservadora(0:24:42) - Pesquisa revela que Game Pass está "canibalizando" jogos triplo A(0:37:53) - Far Cry será adaptado em série de TV antológica(0:47:03) - Rapidinhas(0:56:08) - EncerramentoCRÉDITOSApresentação: Guilherme Dias e Claudio PrandoniRoteiro: Guilherme DiasEdição: Gabriel SalesThumbnail: Lucas G. FerreiraSiga o XdC: YouTube| Instagram | Bluesky | Threads | Tik TokNossas plataformas e redesContato: contato@xdocontrole.comContato para anunciantes e parcerias: comercialxdc@gmail.com
Nos reunimos no pub após mais uma conquista histórica do Crystal Palace. O clube venceu o Liverpool nos pênaltis e sagrou-se campeão da Supercopa da Inglaterra. Além do debate sobre esse jogo neste episódio, damos nossos palpites para a temporada da Premier League. 1:00 Supercopa em Wembley: bastidores e análise em Londres 32:00 Palpites para temporada: Top 6, rebaixados, artilheiro e técnico demitido 56:00 Quiz KTO: João x Senise 1:05:00 Chelsea: montando um belo time 1:10:00 Man City: como chega o time? 1:12:00 Championship 1:15:00 Resenha com barman no pub Learn more about your ad choices. Visit podcastchoices.com/adchoices
Edgard Maciel de Sá, Cauê Rademaker, Phill e Gustavo Garcia analisam a classificação contra o Internacional, a estratégia de Renato no empate e as atualizações do mercado de transferências. DÁ O PLAY!
Bem amigos do Pelada na Net, chegamos em definitivo para o 8 e a faixa! E hoje o Príncipe Vidane comenta o Brasil campeão da Copa América de futebol feminino após mais uma partida lendária da rainha Marta.Esse é um spin-off do Pelada na Net, e está disponível em vídeo no Spotify!site https://peladananet.com.br | bsky @peladananet.com.br | twitter @PeladaNET | instagram @PeladaNaNet | grupo no telegram https://t.me/padegostosodemaisSiga os titulares:Maidana – Twitter / Instagram / BskyShow do Vitinho – Twitter / Instagram / BskyPríncipe Vidane – Twitter / Instagram / BskyProjetos paralelos:Dentro da Minha CabeçaReinaldo JaquelineFábrica de FilmesContribua com o Peladinha:Apoia.sePatreonChave pix: podcast@peladananet.com.br
O Código do Trabalho tem sofrido inúmeras alterações e o governo acaba de propor mais 100 mudanças, algumas importantes e substanciais. Mas serão elas suficientes para dar competitividade à economia?See omnystudio.com/listener for privacy information.
O governo acaba de propor mais 100 mudanças no Código do Trabalho, algumas importantes e substanciais. Mas serão elas suficientes para dar competitividade à economia?See omnystudio.com/listener for privacy information.
VARzea #321
Have you wondered what drives our immune system to turn against us to cause inflammation and what solutions can you take to resolve and prevent diseases like neuropathy, autoimmunity, cardiovascular disease and more. Dr Warren Lesser takes a deep dive through the nutrition and life changes needed to manage and prevent inflammation. Dr Lesser also discusses histamine disorders and sleep.See omnystudio.com/listener for privacy information.
Eduardo Bolsonaro sentiu de novo.Partiu para ofensas pessoais, como é da sua índole, diante da constatação – ilustrada em meu vídeo viral – de suas contradições políticas.Na pandemia, defendeu retoricamente a economia. No tarifaço, ajuda a sabotar a economia, inclusive do estado que o elegeu.Ele se diz em luta pelas “liberdades”.“Eu, diferente de você, sempre lutarei contra a tirania, independente do disfarce que use.”Diferente de mim, na verdade – posto que em 2019 eu já defendia a contenção da escalada autoritária do STF pela via constitucional do Senado -, Eduardo Bolsonaro turbinou em 15 de setembro daquele ano a campanha de sua família contra a CPI da Lava Toga, que investigaria a abertura do primeiro inquérito relatado por Alexandre de Moraes.Na época, seu irmão Flávio era investigado por peculato e precisava da boa vontade no STF de Dias Toffoli e Gilmar Mendes, que seriam alvos da CPI. Essa cronologia pode ser lida no meu artigo “6 anos de inquérito das fake news: conheça sua verdadeira história” –Eduardo se recusou a combater na raiz o que chama hoje de tirania. “A quem interessa?”, perguntava Flávio. “Vamos tocar o barco”, dizia seu pai, Jair Bolsonaro, que logo abraçou Toffoli e exaltou Gilmar.Moraes já tinha censurado reportagem verdadeira da revista Crusoé (em 15 de abril de 2019) e alvejado dois procuradores da Lava Jato, além da apuração da Receita Federal sobre esposas dos ministros supracitados do STF, mas Eduardo, se lutou por algo na ocasião, foi pela “liberdade” do irmão mais velho.Agora, em julho de 2025, ele defende a tarifa de 50% sobre produtos brasileiros, imposta pelo presidente do país que é o maior destino de exportações de São Paulo; arroga-se o crédito por ter influenciado a decisão prejudicial aos exportadores do Brasil; e, como quem deixa o país refém dos interesses de sua família, cobra do Congresso a aprovação de anistia ampla, como solução para a derrubada da medida de Donald Trump. Tudo para garantir a “liberdade” de seu pai, réu no STF por trama golpista – ou seja, por ter tomado uma série de iniciativas em prol de uma tirania para chamar de sua, que só não foi alcançada porque a cúpula do Exército e da Aeronáutica se recusou a apoiar o golpe.Dos Estados Unidos, para onde fugiu quando não era alvo de inquérito algum, e onde vive sustentado pelo pai, Eduardo acusa de “covarde na defesa das nossas liberdades” quem ficou no Brasil, vigiando e criticando diariamente em artigos, reportagens e programas as pessoas mais poderosas do país – incluindo não só o ministro no qual a família Bolsonaro foca seus ataques por interesse personalíssimo, mas os que fazem sua retaguarda e aos quais a família não ousa exercer a mínima crítica, já que obteve deles os desejados votos e decisões em processos sobre funcionalismo fantasma, enquanto celebrava o desmonte da Lava Jato.Ignoro aqui as ofensas pessoais, claro, porque são matéria de outro departamento. Mas elas ilustram, mais uma vez, o incômodo de Eduardo com um jornalista não cooptado que, há mais de 6 anos, aponta a ajuda dos Bolsonaro a Lula, reforçada agora por essa afetação delirante de grandeza e heroísmo patriótico em meio à própria sabotagem da economia nacional.Sentiu demais, hein.Papo Antagonista é o programa que explica e debate os principais acontecimentos do dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores. Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade. Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade. Ao vivo de segunda a sexta-feira às 18h. Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista https://bit.ly/papoantagonista Siga O Antagonista no X: https://x.com/o_antagonista Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais. https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344 Leia mais em www.oantagonista.com.br | www.crusoe.com.br
Treatments of migraine, allergies, vision loss, dry eye and more are far more advanced than you think. Dr Chip Wood of Wood’s Vision Source has more complete and advanced answers to more of your eye questions and concerns. Dr Wood has been my doctor of choice for 15years and he explains options for so many eye disorders in one episode. You will leave this podcast understanding eye health and its direction for the future for you and your family. See omnystudio.com/listener for privacy information.
Eduardo Bolsonaro culpou Alexandre de Moraes e minimizou a influência de Lula na decisão de Donald Trump de taxar produtos brasileiros.O deputado licenciado escreveu no X: “Lula contribuiu, é verdade. Mas o principal culpado pela Tarifa-Moraes chama-se Alexandre de Moraes.Se ele não tivesse prendido inocentes em massa, assassinado Clezão, expulsado X, congelado contas da Starlink, impedido operação da Rimble e Truth no Brasil, acelerado processo contra Jair Bolsonaro e seus apoiadores, ter dado missão para Benedito Gonçalves cumprir, interferido na eleição de 2022 e etc, jamais teríamos a Tarifa-Moraes de 50%.A boa notícia é que para retirar a Tarifa-Moraes basta fazer o oposto.”Felipe Moura Brasil e Ricardo Kertzman comentam:Papo Antagonista é o programa que explica e debate os principais acontecimentos do dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores. Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade. Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade. Ao vivo de segunda a sexta-feira às 18h. Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista https://bit.ly/papoantagonista Siga O Antagonista no X: https://x.com/o_antagonista Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais. https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344 Leia mais em www.oantagonista.com.br | www.crusoe.com.br
Bem amigos do Pelada na Net, chegamos em definitivo para o programa 736! E hoje temos o Príncipe Vidane, Show do Vitinho e Maidana lamentando uma final entre europeus.E neste programa falamos sobre as semifinais da Copa de Mundo de Clubes nas quais o Fluminense terminou sua heroica jornada ao perder pro Chelsea e o Real Madrid foi obliterado por um Paris Saint-Germain avassalador. Também comentamos a tatuagem da maior fã do Thiago Galhardo, falamos sobre o suposto desejo do Flamengo de se desfazer de Pedro, debatemos a condenação fiscal de Carlo Ancelotti, além de muito mais!ORIGINAIS DO FUT - Acesse www.originaisdofut.com, use o cupom PELADA10 para 10% de desconto! E siga a @originaisdofut_ no instagramIRON STUDIOS - Com o cupom PELADA10 você tem 10% de desconto nas estátuas do Maradona e Anderson Silva!#MÃONÃOÉMAISMÃOsite https://peladananet.com.br | bsky @peladananet.com.br | twitter @PeladaNET | instagram @PeladaNaNet | grupo no telegram https://t.me/padegostosodemaisSiga os titulares:Maidana – Twitter / Instagram / BskyShow do Vitinho – Twitter / Instagram / BskyPríncipe Vidane – Twitter / Instagram / BskyProjetos paralelos:Dentro da Minha CabeçaReinaldo JaquelineFábrica de FilmesContribua com o Peladinha:Apoia.sePatreonChave pix: podcast@peladananet.com.brColaboradores de Junho/2025!Seguem os nomes de alguns dos queridos que colaboraram com ao menos R$5. Obrigado a todos! :)[...] Adryel Romeiro | Aline Aparecida Matias | Antonino Firmino Da Silva Neto | Arthur Meister Wistuba | Bruno Kellton | Bruno Marques Monteiro | Bruno Padula Morilla | Carlos Eduardo Ardigo | Daniel Pandeló Corrêa | Débora Mazetto | Elisnei Menezes De Oliveira | Evilasio Costa Junior | Fabio Simoes | Felipe Brasil | Felipe De Amorim Prestes | Gabriel Frizzo | Gabriel Lecomte | Gabriel Lopes Dos Santos | Gabriel Matte De Moura | George Alfradique | Gian Luca Barbosa Mainini | Guilherme Da Hora | Gustavo Henrique Rossini | Jailson Gomes | João Pedro Machareth | Luan Germano | Luca Vianna | Lucas De Oliveira Andrade | Marcelo São Martinho Cabral | Marcio Leandro Lima Dos Santos | Marco Antônio Maassen Da Silva | Marianna Feitosa | Mario Peixoto | Matheus Andion De Souza Vitorino | Matheus Bezerra Lucas Bittencourt | Maxwell Dos Santos Nelle | Pedro Bonifácio | Pedro Henrique Tonetto Lopes | Rafael Manenti | Rafael Matis | Rainer Almeida | Raphael Piccoli | Raphael Pini Bubinick | Rodrigo Oliveira Porto | Stéfano Bellote | Thiago De Souza Cabral | Thiago Nogueira Marcal | Thomas Rodrigues | Tiago Weiss [...]Obrigado por acreditarem em nós!Comente!Envie sua cartinha via e-mail para podcast@peladananet.com.br e comente tanto no post do Instagram com a capa deste episódio quanto no Spotify (se batermos 50 comentários em cada, leremos comentrouxas no programa que vem)!
For this special episode of the Houses on the Moon Podcast, Amy Gottlieb (U.S. Migration Director for the American Friends Service Committee, and HOTM board member) interviews New Yorker staff writer Jonathan Blitzer about his book "Everyone Who is Gone is Here: The United States, Central America, and the Making of a Crisis." Amy and Jonathan discuss the complex history of US-Central American relations and the themes that inspired our original documentary play and podcast series, “De Novo.” Special thanks to Cory Choy and Tom Fama at Silver Sound Studio for recording this interview and to Will Coley for producing and editing this episode. Music by Greg Kirkelie via Free Music Archive. Learn more about your ad choices. Visit megaphone.fm/adchoices
Edgard Maciel de Sá, Cauê Rademaker, Phill, Marcello Neves e Renné Valente analisam a vitória sobre o Al Hilal, o simbolismo do gol de Martinelli e os desfalques para o jogo contra o Chelsea. DÁ O PLAY!
We all have a metabolic type that affects everything from mood, energy, disease development and more. Your metabolic type is expressed in mood, energy weight, disease development and more. Martin Pytela gives a thorough overview of how your metabolic type and digestive system controls these major aspects of health and how to manage it. His story is compelling. Life-enthusiast.comSee omnystudio.com/listener for privacy information.
No NerdCast de hoje vamos falar sobre a onda de reboots no cinema, séries e até games: vale a pena? Bora conversar sobre continuações que surpreenderam, reboots que ninguém pediu e quando é que a gente realmente precisa de algo novo. A PRÓPRIA CARNE Trailer Oficial de A Própria Carne: https://youtu.be/qg5ibXsMG9Y Cadastre-se e acompanhe as novidades: https://jovemnerd.page.link/A_Propria_Carne_Tour Atenção! Estamos nos preparando para o lançamento de A Própria Carne e queremos saber: de qual estado e cidade você gostaria de assistir ao filme? https://docs.google.com/forms/d/e/1FAIpQLScyabqbGvNJHqFp7VR-Z9Bi5QJo-SVc0DVnbiz48apxbNdZkw/viewform NERDSTORE Confira os lançamentos das novas camisetas da NerdStore: https://nerdstore.page.link/Lancamentos_NerdStore_NerdPlayer LUIZALABS Ouça o Nerd na Cloud deste mês: https://jovemnerd.com.br/podcasts/nerd-na-cloud/design-de-ux-inteligente-faz-o-usuario-inteligente/ Instagram @Luizalabs: https://jovemnerd.page.link/Luiza_Labs_Instagram_NC Página de Carreiras: https://jovemnerd.page.link/Carreiras_Magalu_Nerdcast Let's Labs: https://jovemnerd.page.link/Lets_Labs_NerdCast CAVERNA DO DRAGÃO: O EPISÓDIO PERDIDO Confira o curta Ganhador do Leão de Ouro em Cannes 2025: https://youtu.be/m_mFdMVKHTs > SIGA O NOVO FEED DO CANECA DE MAMICAS < CONFIRA OS OUTROS CANAIS DO JOVEM NERD E-MAILS Mande suas críticas, elogios, sugestões e caneladas para nerdcast@jovemnerd.com.br APP JOVEM NERD: Google Play Store | Apple App Store ARTE DA VITRINE: Randall Random Baixe a versão Wallpaper da vitrine EDIÇÃO COMPLETA POR RADIOFOBIA PODCAST E MULTIMÍDIA